Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.

ABSTRACT:

Background

Because of the recent grade C draft recommendation by the US Preventive Services Task Force (USPSTF) for prostate cancer screening between the ages of 55 and 69 years, there is a need to determine whether this could be cost-effective in a US population setting.

Methods

This study used a microsimulation model of screening and active surveillance (AS), based on data from the European Randomized Study of Screening for Prostate Cancer and the Surveillance, Epidemiology, and End Results Program, for the natural history of prostate cancer and Johns Hopkins AS cohort data to inform the probabilities of referral to treatment during AS. A cohort of 10 million men, based on US life tables, was simulated. The lifetime costs and effects of screening between the ages of 55 and

SUBMITTER: de Carvalho TM 

PROVIDER: S-EPMC6680244 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature